

ONCOLOGY Insider

City-Wide Newsletter



SPOTLIGHT ON IMPACTFUL: DR. ANN CHAMBERS

Sincere gratitude and best wishes to Dr. Ann Chambers (Distinguished Oncology Scientist, LHRI; Professor, Dept. of Oncology, Pathology & Laboratory Medicine, Medical Biophysics, UWO) on her retirement from Lawson Health Research Institute and the University of Western Ontario after 35 years of exemplary service and dedication to our cancer research community.

As you know, Ann has been a steadfast pillar of our research community throughout her career, and has made an indelible mark on breast cancer research both nationally and internationally. She was a pioneer and strong proponent of translational cancer research, and is responsible for initiating the movement toward disease-seated research programs within the Cancer Research Laboratory Program at the LRCP. She has amassed a stellar publication record, with an h-index of 91; her work having been cited >27,000 times. Ann is a world-renowned expert in breast cancer metastases, and her research has led to paradigm-shifting contributions to the understanding of the deadly process of metastasis. This work includes the development and application of novel ways to image metastases, the identification of dormant cancer cells that resist treatment and later form metastases, and the development of biomarkers of cancer progression. She has been instrumental in putting London on the cancer research map, and has worked tirelessly to promote cancer research in Canada in a leadership capacity; Ann was a driving force within the former National Cancer Institute of Canada (NCIC) where she was a member of the NCIC Advisory Committee on Research from 2001-2009, with postings as Vice-Chair from 2004-2005 and Chair from 2006-2007. She was also a member of the NCIC Board of Directors from 2005-2007 and sat on the NCIC Investigational New Drug Committee Executive from 2005-2009. Her accomplishments in cancer research have been recognized by numerous prestigious awards and honours, including the Women of Distinction Award (London YMCA-YWCA, 1999); a Queen's Golden Jubilee Medal (Office of the Governor General of Canada, 2002); the Hellmuth Prize in recognition of outstanding achievement in research (University of Western Ontario, 2011), and being named as a Fellow to the Canadian Academy of Health Sciences (2012).

Locally, Ann's leadership is best exemplified by her development of the Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit (TBCRU) at the London Regional Cancer Program in 1998. It was the first translational cancer research program in London, and Ann's work set the

INSIDE

1	SPOTLIGHT ON IMPACTUFUL
3	SPOTLIGHT ON GRANTS
5	SPOTLIGHT ON INNOVATIVE
7	SPOTLIGHT ON R&E DAY
. 9	SPOTLIGHT ON STRATEGY
10	SPOTLIGHT ON INTEGRATED
12	SPOTLIGHT ON CBME
14	SPOTLIGHT ON LHSF



SAVE THE DATE

Research & Education Day June 8, 2018


NEWSLETTER

Questions & Comments:

Kimberly.trudgeon@lhsc.on.ca

Phone: 519.685.8500 x75395

Created by: Kimberly Trudgeon



stage for a transition toward this research paradigm that demonstrates her

dedication to improving the lives of cancer patients and their families. Ann was a strong advocate of patient involvement in cancer research and developed strong ties with cancer survivors while empowering them to help us in the journey toward new therapies.

The TBCRU, under Ann's leadership, is a strong, multi-faceted program dedicated to translational breast cancer research. The TBCRU's strong collaborative relationship with the Breast Cancer Society of Canada (BCSC) has been an enviable model of community involvement in cancer research. Her deep commitment to training the next generation of breast cancer researchers is obvious from the large number of BCSC-TBCRU graduate student scholarships that were awarded annually through a competitive process. As well, her mentorship of Dr. Alison Allan (TBCRU Scientist, Associate Professor and Chair, Dept. of Anatomy & Cell Biology, UWO) has appropriately situated Alison to assume responsibility as the next Director of the TBCRU. Ann and Alison have worked closely with the Breast Cancer Society of Canada to export their successful collaborative model of translational research to other major research institutions across Canada.

Ann has been an ardent proponent of integrating cancer researchers with frontline cancer care physicians. She has supported the need for more clinician scientists, and for protecting time to allow oncologists to do research and to collaborate with our cancer scientists. She is a model of success for women in science today, her contributions having been significantly influential to the expansion and growth of translational cancer research and breast cancer research both locally and across Canada.

We thank Ann for her numerous contributions to an integrated cancer research program that values synergy between discovery science and its impact on patient care, and wish her the very best as she begins this new chapter in her life.

Drs. G. DiMattia, G. Bauman, A. Allan, D. Hill, A. Allan, J. Mymrk

SPOTLIGHT ON IMPACTFUL

DR. GEORGE RODRIGUES

At the 2018 annual American Society for Radiation Oncology our own Dr. George Rodrigues was inducted as a Fellow of ASTRO (FASTRO), one of a very few Canadian Radiation Oncologists receiving this honor. The Fellows Program, started in 2006, honors those that have been an Active, Emeritus or International member of ASTRO for at least 15 years, have given the equivalent of 10 years of service to ASTRO and have made significant contributions to the field of radiation oncology in the areas of research, education, patient care or service and leadership. Dr. Rodrigues was recognized for his ongoing contributions to guidelines development within ASTRO, leading and contributing to important clinical practice guidelines in the areas of lung cancer and prostate cancer treatment.

ANNOUNCEMENT:



Dr. Alison Allan

Dr. Alison Allan has been appointed as Chair, Anatomy and Cell Biology, Schulich School of Medicine & Dentistry, Western University effective February 1, 2018 until June 30, 2023.

LINK HERE



Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit

Dr. Alison Allan also been announced as Director of the Translational Breast Cancer Unit (TBCRU) as of March 1st, 2018. More info about the TBCRU located here



London Health Sciences Centre

Dr. Paul Woods President and Chief Executive Officer

On March 12 and 16, LHSC's new President and CEO Dr. Paul Woods hosted a series of town halls for all staff and physicians to share more about LHSC's strategic planning, renewed mission, vision and values, as well as the priorities the hospital will be focusing on in the coming weeks and months. Link Here

Be sure to check out the Giants 2.0 of **Research** Slide from his PowerPoint Presentation. We celebrate our Giants together!

Study to ease collateral damage of cancer treatment DR. ALEX LOUIE



Dr. Alex Louie, Radiation Oncologist is examining new radiation techniques that could avoid damaging the esophagus for millions of people with advanced lung cancer.


for his ongoing contributions to guidelines development within ASTRO, leading and contributing to important clinical practice guidelines in the areas of lung cancer and prostate cancer treatment.

Click Here for the full story by Paul Mayne

LAWSON RESEARCHERS AWARDED \$ 4.4 MILLION **GRANT** - PERSONALIZED MEDIDINCE



Personalized medicine is the analysis of a patient's DNA to predict how they will respond to medications. Led by Dr. Richard Kim, scientist at Lawson Health Research Institute (Lawson) and clinical pharmacologist at London Health Sciences Centre (LHSC), researchers at Lawson have received \$4.4 million to study an expanded personalized medicine program at LHSC. One third of the funding comes from the provincial government's Ontario Research Fund (ORF) while the remainder is contributions from Thermo Fisher Scientific and donor funding through London Health Sciences Foundation. Full article here



CONGRATULATIONS! NSERC GRANT RECIPIENTS!

DR. LEN LUYT

Chemical Technology for Imaging Agent Discovery, Year 1 of 5, \$58,000

DR. JOSEPH TORCHIA

Regulation and function of active DNA demethylation in Cellular Differentiation

Year 1 of 5, \$ 39,300

CIHR GRANT RECIPIENTS:

Please join us in offering congratulations to Lawson and Western cancer researchers, Drs. James Koropatnick, Fred Dick and Joe Torchia on their success at obtaining individual CIHR Project Grant funding in the last competition!

This is absolutely fantastic news for these investigators especially in this climate of reduced funding and increased competition! We applaud their success and the hard work and diligence of their laboratory personnel who contributed to their applications!

We recognize the continued perseverance and dedication of all cancer scientists, locally, who compete for research funding at the national and international level. It is only with this level of commitment to our work can we continue to strive to make a positive impact in the lives of cancer patients, to train new cancer scientists and bring new knowledge to bear on the diagnosis and treatment of this disease.

Congratulations on your success! Keep up the great work!

Fred Dick (Professor, Depts of Biochemistry, Oncology): Epigenetic regulation of repeat expression by RB and EZH2 in cancer (5-years of funding)

Joe Torchia (Professor, Depts of Biochemistry, Oncology): The role of dynamic DNA methylation in gene regulation and cancer (5-years of funding) (Co-Applicant: Dr. M. Underhill, UBC)

James Koropatnick (Professor, Depts of Oncology, Micro/Immunology): Inducing Mismatch Repair Deficiency in Cancer Cells for Therapeutic Benefit (5-years of funding) (Co-Applicant: Drs. Wei-Ping Min, Xiufen Zheng, & Saman Maleki, Western)

WE CELEBRATE: WORLDISCOVERIES

Matthew Hebb MD, PhD, FRCSC

INNOVATOR
OF THE YEAR

More details here

INTEGRATED.
INNOVATIVE.
IMPACTUFL.

CONGRATULATIONS!

Charles Ishak, PhD Dr. Fred Dick's Lab

BIOCHEMISTRY AWARD

More details here

SPOTLIGHT ON IMPACTFUL: RESIDENT RESEARCH

Mary Mahler (PGY2 internal medicine)

took a poster, supervised by Eric Winquist and Richard Kim to Head and Neck Cancer Symposium. "The effect of MATE1 polymorphisms on cisplatin efficacy in the treatment of head and neck cancer." Drs. Sara Kuruvilla, Dan Breadner, Anthony Nichols and David Palma were among the authors.

Dan Breadner (PGY4, Medical Oncology)


Awarded an oral presentation at the CAMO annual meeting on April 26th "Health Related Quality of Life in Elderly or Frail Patients with Advanced Colorectal Cancer Treated with Dose Reduced Capecitabine".



On April 5, a **CRLP Tour** for 11 people was given by Dr. Gabriel DiMattia, Interim Director, CRLP and Pam Taylor of LHSF. We especially want to thank Dr. Lori Lowes, Research Associate in Dr. Alison Allan's lab as well as Kara Ruicci, MD/PhD candidate in Dr. Anthony Nichols' lab for providing a short synopsis of their work. Their participation and promotion of our cancer research to the London community was greatly appreciated by all.



NEWS FROM DR. JOE MYMRYK'S LAB



PhD Candidate Steven Gameiro presents a public lecture for CCS RIOT for World Cancer Day for Feb 4, 2018 at Covent Garden Market.

Title: Virally induced cancers

Dr. Cason King successfully defended his PhD thesis, earning his doctorate on Feb $16^{\rm th}$.


His thesis was titled:

"Functional and Structural Mimicry of A-Kinase Anchoring Proteins by Human Adenovirus E1A"



Dr. King - Published paper in J. Virology on Jan 24th

Mimicry of cellular A kinase anchoring proteins is a conserved and critical function of E1A across various human adenovirus species. Article Here







CONGRATULATIONS!

Dr. Joe Mymryk

Distinguished Oncology Scientists, CRLP & Professor Depts. of Micro/Immunology, Oncology, Otolarygngology

RECIPIENT OF 2018 - Schulich Award of Excellence

Inaugural Western University Award for Faculty Mentorship



NEWS FROM DR. ALISON ALLAN'S LAB

New Publications

- 1. Eigl B.J., Chi K.N., Tu D., Hotte S., **Winquist E**., Booth C., Canil C., **Potvin K**., Gregg R., North, S., Zulfiqar M., Ellard S., Ruether J.D., Le L., Kakumanu A., Salim M., **Allan A.L.**, Feilotter H., Theis A., and Seymour L.K. A randomized phase II study of pelareorep in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic castration resistant prostate cancer: Canadian Cancer Trials Group study IND 209. *Oncotarget*, 2018;9(8):8155-8164.
- 2. **Lowes L.E.** and **Allan, A.L.** Epithelial-to-mesenchymal transition (EMT) in circulating tumor cell (CTC) characterization. *Adv Clin Chem.* 2018;83:121-181.

Conference Presentations

- 1. **Lowes L.E. and Allan A.L.** Circulating tumor cell (CTC) analysis in pre-clinical models of cancer metastasis. 2nd Annual Tumor Models San Francisco Meeting, San Francisco CA, January 23-25, 2018 [invited oral presentation, Lori Lowes]
- Scher H.I, Graf R.P, Schreiber N.A., Winquist E., McLaughlin B., Lu D., Orr S., Fleisher M., Lowes L.E., Anderson A.K.L., Wang Y., Dittamore R.V., Allan A.L., Attard G., and Heller G. Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC). American Society of Clinical Oncology (ASCO) 2018 Genitourinary Cancers Symposium, San Francisco, CA, February 2018.

Thesis Defenses:

Congratulations to Ashkan Sadri, graduate student in the Allan lab, for successful defense of his MSc thesis in Anatomy & Cell Biology entitled "Influence of the metastatic microenvironment on stem-like human breast cancer cells" (January 2018).

Other News:

Featured Researcher, Alison Allan
Canadian Cancer Society Research Stories of 2017
(http://www.cancer.ca/en/about-us/our-research/research-impact/?region=on);
highlighting their most impactful research of the year.





Congratulations Dr. Saman Maleki!

Dr. Maleki, Adjunct Research Professor at the Department of Oncology

METIOR incubator

The first METIOR Incubator meeting was hosted by Dr. Carl June at UPenn and successfully completed (picture attached). They are off to London in September for their second meeting. The last meeting will be held in Washington DC in November.

METIOR incubator is the first of its kind Immunotherapy educational program that is organized by the Society for Immunotherapy of Cancer (SITC). The program mentors are world-renowned scientists and clinicians active in the field of Immuno-Oncology. The 10 participants (academic and industry scientists and clinicians) were selected from a pool of applicants, from around the world, with impressive CVs. They have received a small team grant from SITC to work on two projects together. https://www.sitcancer.org/education/sparkathon/2017-cohort/projects/metior

London had to compete with several other centers to host this event including MD Anderson, Roswell Park, and Providence cancer center (Oregon).

15th ANNUAL ONCOLOGY RESEARCH & EDUCATION DAY FRIDAY, JUNE 8TH, 2018

"Where exceptional cancer care, research and education unite."

Oligometastatic disease, the immune system and image-guided radiotherapy – A new paradigm in personalized medicine.

Keynote Speaker

Dr. Suresh Senan



Conference Co-Chairs:

Dr. Alex Louie Dr. Stewart Gaede

Conference Coordinator:

Luciana Brown

ABSTRACT SUBMISSIONS:

Click Here

Open March 26, 2018 Close April 18, 2018

REGISTRATION:

Click Here

Open April 6, 2018 Close June 1, 2018

More Details and Submission forms

AWARDS:

AWARDS (Nominations now open)

Awards are available to be won in the following categories:

Best Oral Presentations (2)

Best Poster Presentations (6)

Department of Oncology Excellence in Academic and Teaching Awards (5)

Divisions of Surgical Oncology Radiation Oncology Medical Oncology Experimental Oncology Windsor Oncology

Nominees from the five areas exemplify outstanding contributions to teaching trainees, colleagues and staff. Their contributions should demonstrate excellent or innovative teaching that has a lasting impact.

Submit your nomination letter for the Academic and Teaching Awards to the respective Division Leader for consideration by **no later than Friday May 25, 2018**.

Denise Power Cancer Research Staff Award of Excellence (1)

Nominees exemplify truly dynamic, hardworking individuals in Cancer Research who contribute to their own research group and the greater CRLP/LRCP work environment.

Submit all nomination letters to Luciana Brown (luciana.brown.@lhsc.on.ca) by **no later than Friday May 25, 2018.**

NEWS FROM INTERIM DIRECTOR OF CRLP DR. GABE DIMATTIA

- ▶ Dr. Fred Dick has published an article in Nature Reviews which will changes our understanding of the best known and arguably the most important tumour suppressor protein we know of, pRB. This is a major achievement given that it was an invited review. Access Article Here
- > **Dr. Jeremy Burton** at St. Joes and Dr. Saman Maleki Research Associate, CRLP and Adjunct Research Professor, Dept. of Oncology) were awarded:

Project Title:

Combining Fecal Microbial Transplant (FMT) and anti-PD-1 immunotherapy for the treatment of melanoma patients

Co-PIs: Drs. Saman Maleki and Jeremy Burton

Co-applicants: Drs. John Lenehan and Michael Silverman Funding: \$100,000 Support period: 2 years

Complete Summary:

Immunotherapy has revolutionized the management of patients with advanced melanoma. However, many patients do not respond to these drugs. Recently, a plethora of clinical studies in various malignancies, including melanoma, has established a direct link between gut microbiome and response to immunotherapy. Patients with diverse healthy microbiome and proficient intestinal barrier function are more likely to respond to immunotherapy. Therefore, establishing a healthy gut microbiome in melanoma patients holds the promise of rendering them responsive to immunotherapy. We hypothesize that modifying melanoma patients' microbiome with Fecal Microbial Transplant (FMT) from a healthy donor is safe and will enhance patient's gut barrier and response to immunotherapy.

Objectives:

- 1- To examine the safety of combining FMT with immunotherapy in melanoma patients.
- 2- To examine changes in immune blood biomarkers and microbiome profile of patients before and after FMT.
- 3- To measure the efficacy of immunotherapy in these patients. <u>Full Details Here</u> <u>https://www.ourmicrobiome.org</u>)
- Congratulations to Dr. Trevor Shepherd who will be presenting his research at the University Of Minnesota.



CONGRATULATIONS TO DR. BART KOLENDOWSKI

April 9th, Bart successfully defended his PhD thesis entitled "The role of Thymine DNA glycosylase in transcriptional regulation." Bart gave an excellent talk and was able to address the numerous questions from the examiners.

Thank you to Dr. Fred Dick and Dr. Joe Mymryk for their contributions as committee advisors.

Good luck to Dr. Bart Kolendowski as he moves on into a future career in research!

DEPARTMENT OF ONCOLOGY

STRATEGIC PLAN 2017-2022 1 YEAR LATER...





February 2017 we launched the Department of Oncology Strategic Plan with the Vision, "Where exceptional care, education and research unite to improve the future for cancer patients." Since launching the plan, our Faculty and Leaders have implemented 'Strategies of Excellence' including advancing the work of the Goals of Care and Advanced Care Planning Groups; increasing the 'Department of Oncology Capacity' through supporting our Passionate and Purposeful People including recruiting new Oncologists (Drs. Morgan, Fernandes and Raphael) and a Research Associate (Morgan Black) within the Division of Medical Oncology and recruiting a new Oncologist (Dr. Laba) and piloting a new model of protected academic time within the Division of Radiation Oncology. We also launched a Wellness and Resiliency Committee that has organized Grand Rounds dedicated to Wellness topics, has developed a Wellness manual for Faculty and is organizing pilot educational sessions around mindfulness training.

Within our Division of Experimental Oncology, we look forward to the recruitment of a Baines Imaging Scientist to expand the capacity of our translational cancer imaging research teams and within the Division Surgical Oncology work continues on the implementation of The National Surgery Quality Index Program, a key strategy for excellence in integrated, impactful and innovative clinical care. Finally we continue to work on the implementation of Competency Based Medical Education Curricula across our Residency and Undergraduate Programs, in alignment with our goals of developing our Faculty and providing Excellent, Innovative and Impactful training programs. Full details on our Strategic Plan are available at: www.schulich.uwo.ca/oncology/strategic planning/index.html and we look forward to advancing many other initiatives over the coming year!







WELLNESS COMMITTEE UPDATE



SPOTLIGHT ON INTEGRATED


MEDITATION & LEADERSHIP RETREAT

The Department of Oncology held its first Mediation & Leadership Retreat on Saturday March 28, 2018 at the Ivey Spencer Leadership Centre.



Guy Gaudry, recognized Zen/Meditation Teacher and Certified Executive Coach, along with **Dr. Maria MacDonald**, LRCP Neurologist in Oncology, facilitated a secular one day meditation and leadership retreat to 20 faculty and staff. Meditation, as a particular open and accepting way of paying attention, is evidence based approach to decrease burnout in professionals and improves many health measures in a variety of populations... including physicians and professionals!





WELLNESS HANDBOOK

This handbook includes:

- Western, LHSC and community contacts and resources
- Dike Drummond's "Stop **Physician Burnout**" summary by Dr. **Francisco**
- A variety of articles including OMA The Basics, and The Five Fundamentals of Civility for Physicians Kaufmann, MD

View the Wellness Handbook HERE

Improving work-life balance has been identified as a concern among staff and faculty surveys conducted through LHSC and Western. Wellness & Resiliency Task Force has been created to promote and support strategies to enhance resiliency and work-life balance among staff and faculty in the Department of Oncology. The purpose of this handbook is to create awareness and act as a resource by providing points of contact/support, articles and guides that are available online and through Western, LHSC, and the surrounding community.



The **Cures4Glioma (C4G) Network** has a monthly meeting that anyone with interest in high-grade glioma research is encouraged to attend. This network was formed in 2016 by Drs. Matthew Hebb and John Ronald to bring together clinicians, imaging scientists, cancer biologists, and other fundamental scientists and trainees/residents within London and beyond to expedite research into glioma biology, the discovery and development of novel treatment paradigms, improved methods for glioma detection, characterization and treatment monitoring, and advanced animal model development (transgenic models, patient-derived xenografts).

Our network's long-term goal is to translate our discoveries and innovations into glioma patients for improved quality of life and survival.

We have specific interest in capitalizing on our interdisciplinary research expertise by forming new collaborations. Our group is committed to finding new funding opportunities for glioma research and to share current funding resources and supplies to help spur new research directions through pilot studies.

We are very appreciative of recent internal Western funding success that will help support brand-new initiatives from our network including:

- 1. An "Interdisciplinary Development Initiative (IDI) in Stem Cells and Regenerative Medicine Research Award" (\$15,000) To Drs. John Ronald, Paula Foster and Matt Hebb, to explore the use of stem cells for the delivery of therapeutic payloads into patient-derived GBM xenografts.
- 2. A Collaborative Research Seed Grant from the Schulich School of Medicine & Dentistry (\$49,600) To Drs. Silvia Penuela, Matt Hebb and John Ronald, to evaluate the role of Pannexin 1 on patient-derived GBM growth in the chick model using bioluminescence imaging.

If you are interested in this group, please email <u>John Ronald</u> (<u>jronald@robarts.ca</u>) to be added to our email list. Meetings occur every 3rd Wednesday of each month and can be attended via GoToMeeting or in person at Robarts Research

CONGRATS TO THE CRLP WINNERS:

THANK YOU SO MUCH for supporting the **Cancer Research Laboratory Program** Wine basket raffle! It was a resounding success in large partly to the persistence and dedication from our amazing administrative staff, **Charlene Manax and Gail McConnell** with help from Gail Howard, Kay McIntyre and Juanito Isaguirre. Special thanks to Annie Johnstone, Ambulatory Clerk, Cancer Services for drawing the tickets for us.

1st Prize: *Dan Kimmerly, ESW, Environmental & Support Services* **2nd Prize:** *Melissa Watson, Tim Horton's B-Tower*

3rd Prize: Anita Bunnie, Team Assistant, Southwestern Maternal, Newborn, Child & Youth Network Children's Care









ONCOLOGY CBME

Faculty Development



Time-based --→ Competency-based

Medical Education

CBME Rationale:

- Focusing on outcomes
- Emphasizing abilities
- De-emphasizing time-based training
 - Promoting greater learner-centeredness

CBME RESOURCES:

The Competence by Design (CBD) initiative is gaining momentum. Some of our disciplines are already actively engaged in CBD, and many other disciplines are scheduled to make the change in the next few years.

HELPFUL WEBSITE LINKS: ROYAL COLLEGE CBME WESTERN CBME Oncology

ONCOLOGY CBME CLINICAL FACULTY RETREAT:

Saturday, May 12, 2018 8:00 am - 4:00 pm &

Saturday, June 16, 2018 8:00 am - 4:00 pm

REGISTRATION IS OPEN

Location:

Ivey Spencer Leadership Centre 551 Windermere Road



Western Resources:

Competency Based Medical Education

Tech Resources Link

Royal College Resources:

Meantime Guide

QUESTIONS? Please direct any questions to kimberly.trudgeon@lhsc.on.ca



The Centre for Translational Cancer Research (CTCR) is a diverse and growing network of cancer researchers who seek to minimize the burden of cancer.

On February 2, 2018, cancer researchers, scientists, physicians, learners and supporters from across London Health Sciences Centre, Robarts, Lawson Health Research Institute, Western University, and the Schulich School of Medicine and Dentistry joined forces at our 2ND Annual Collaboration event.



Thank you to **Dr. Paul Woods LHSC, CEO** for opening our event and for sharing his personalized his connection to Translational Cancer Research and Treatment. Dr. Woods shared a snapshot of his vision for LHSC as a health ecosystem with a tripartite mission of: **CLINICAL CARE + RESEARCH + EDUCATION**

Sincere gratitude to **Dr. Mick Bhatia** from McMaster University for joining our event and his inspiring keynote address and passion for cancer research. Many exciting takeaways from his TED-style presentation including his 3-ring model of successful translational research.

Creative designs of a futuristic staff lounge, called the **STAFF THINK TANK** to help further promote collaborations.

A few of the exciting think

tanks created by attendees.





11 You Retweeted

Alison Allan @aallan74 · Feb 2
Fantastic TED · Style talk by Mick Bhatia- accomplished scientist, whiteboard & marker artist and self-described "nerd". Love his 3-ring model of successful translational research #CTCRColleaguesCollaborate

11 You Retweeted

Particular Style St

Dr. Alison Allan won the **Social Media Award!**







Collaboration Sessions were held to explore halfbaked ideas through brainstorming and discussion. Table hosts to briefly explain their ideas or ongoing projects. The purpose of this session was to help move these half-baked ideas forward in London. We will be sure to update you on the success of projects moving forward as a result.

Elizabeth Mazza was celebrated with a farewell and thanked for her contributions to the CTCR and the Department of Oncology. **Kimberly Trudgeon** was welcomed as Project Manager of CTCR.





LHSF UPDATES

Taking a Bold Step in the Fight Against Cancer

A cancer diagnosis: it's a moment that can turn our lives upside down in an instant. For patients whose cancer went undetected just a few years ago — like that of a young father of two whose cancer spread unseen — there is new hope. At places like the Gerald C. Baines Centre for Translational Research, some of cancer's biggest puzzles are being confronted and new discoveries fast-tracked to continue to help patients receive earlier screening and treatment, allowing them to return to their families and lives.

The Baines Centre's expert team of researchers, clinicians and specialists is doing everything in its power to turn today's scientific discoveries into tomorrow's new treatments and breakthroughs in patient care...and with community support, the Baines Centre is getting a potential \$3-million-dollar boost.

On December 13, 2016, the Gerald C. Baines Foundation announced a \$1.5 million commitment in hopes of inspiring the public to join them in reaching the \$3 million needed to expand the capabilities of the Baines Centre.

Donations from the matching gift challenge will be used to acquire advanced equipment and software for an imaging lab in the Baines Centre, as well as fund new research positions and expand clinical trials.

The Baines Centre is a unique facility in Canada where cancer researchers and care providers work side by side to translate new findings in cancer imaging and treatment directly to patient care, removing the traditional separation between lab and clinic.

"Public support through donations helped create the Baines Centre, which opened in 2010 and has become a game changer for improved cancer treatments and better patient outcomes," says Kirk Baines, Chair, Gerald C. Baines Foundation. "We are asking for the public's help again to expand the potential of the Centre even further."

To reach that goal, the Baines Foundation will donate one dollar for every dollar London Health Sciences Foundation (LHSF) receives towards translational cancer research by December 31, 2017.

FUNDRAISING ACHIEVEMENTS

THE CANCER CAMPAIGN:

Fundraising Goal: **\$40M**

Amount Raised:

\$42,545,804

towards the various fundraising priorities!!!





To learn more or to support the Baines Centre, please contact Pamela Taylor, Senior Development Officer, Cancer, London Health Sciences Foundation, at pamela.taylor@lhsc.on.ca

519.685.8721.

ONCOLOGY COMMUNICATION HUB



NEWS + RESOURCES + LINKS + OUTLETS

- ❖ Canadian Institutes of Health Research (CIHR) Institute of Cancer Research
- Lawson Health Research Institute
- Windsor Cancer Research Group
- Windsor Regional Cancer Program
- Centre for Translational Cancer Research (CTCR)
- Ontario Institute of Cancer Research (OICR)
- Robarts Research Institute
- WORLDiscoveries
- London Health Sciences Foundation
- ❖ BioCanRx
- Canadian Cancer Clinical Trials Network
- Cancer Care Ontario
- London Regional Cancer Program
- Department of Oncology
- Canadian Cancer Society
- South West Regional Cancer Program
- Wellspring London and Region
- Cancer RIOT
- Mady Hymowitz (via Mady.Hymowitz@schulich.uwo.ca)
- Kimberly Trudgeon (via <u>Kimberly.Trudgeon@lhsc.on.ca</u>)
- Stacey Dinel (via <u>stacey.dinel@schulich.uwo.ca</u>)
- Donna DeFrancesco (via <u>ddefranc@uhnresearch.ca</u>)
- ❖ Newsletter from Glenn and Neil (via email)
- Oncology Grand Rounds (via Carol.Dolan@lhsc.on.ca)





Gabe Boldt LRCP Library (via Gabriel.Boldt@lhsc.on.ca



"OPEN MIC"

It's your turn to take the mic with Oncology's new initiative aimed to encourage colleagues to send us your anonyms Departmental:

FEEDBACK + SUGGESTIONS + IDEAS + GOALS

Click Here to Share



THANK YOU & STAY TUNED

FOR OUR NEXT ISSUE OF THE ONC. INSIDER Est. 2017